LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Researchers Show How the Influenza Virus Blocks Natural Killer Cell Recognition

By LabMedica International staff writers
Posted on 31 Aug 2014
Print article
Image: Diagram illustrates the innovative process that could lead to more effective drugs against influenza infection (Photo courtesy of the Hebrew University of Jerusalem).
Image: Diagram illustrates the innovative process that could lead to more effective drugs against influenza infection (Photo courtesy of the Hebrew University of Jerusalem).
A team of molecular virologists has described how the influenza virus evolved a defense mechanism to protect it from attack by the immune system's natural killer (NK) cells.

The recognition of pathogen-infected cells by the immune system's NK cells is controlled by inhibitory and activating receptors. Investigators at the Hebrew University of Jerusalem (Israel) had shown previously that among the activating NK cell receptors, the natural cytotoxicity receptors NKp44 and NKp46 interacted with the viral hemagglutinin (HA) protein expressed on the cell surface of influenza-virus-infected cells. The interaction between NKp44/NKp46 and viral HA was sialic-acid dependent, and the recognition of HA by NKp44 and NKp46 led to the elimination of the infected cells.

In the current study, which was published in the August 1, 2014, issue of the Journal of Infectious Diseases, the investigators demonstrated that the influenza virus developed a counter-attack mechanism based on the virus' neuraminidase (NA) protein. The NA enzyme removed HA sialic acid and prevented the recognition of the virus by the NKp44 and NKp46 receptors. This lack of recognition resulted in reduced elimination of the infected cells by NK cells.

Understanding the NA/HA interaction and its influence on NK cell behavior is expected to lead to the development of new approaches for treating influenza.

Influenza is a major global health problem causing approximately three to five million cases of severe illness and leading to between 250,000 and 500,000 deaths worldwide. “It is thus urgent to develop new drugs for fighting influenza infection, which requires an understanding of the virus's life cycle and its interaction with the host’s immune system,” said first author Yotam Bar-On, a research student in immunology and oncology at the Hebrew University of Jerusalem.

In recognition of the significance of his research, Yotam Bar-On was recently awarded the prestigious Kaye Innovation Award. This award was established by the prominent British pharmaceutical industrialist Isaac Kaye to encourage faculty, staff, and students of the Hebrew University of Jerusalem to develop innovative methods and inventions with good commercial potential which will benefit the university and society.

Related Links:

Hebrew University of Jerusalem


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more